Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination

Bibliography

• Anaissie E, Bodey GP. Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 1989;3:867-82
   PubMedGoogle Scholar
• Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 1992;11:99-109
   PubMed Web of Science ®Google Scholar
• Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991;28(Suppl B):1-16
   PubMed Web of Science ®Google Scholar
• Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:3-14
   Web of Science ®Google Scholar
• Marr KA, Carter KR, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson D. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69
   PubMed Web of Science ®Google Scholar
• Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005;56:5-11
   PubMed Web of Science ®Google Scholar
• McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7
   PubMed Web of Science ®Google Scholar
• Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:3-14
   Web of Science ®Google Scholar
• Fridkin S, Jarvis W. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511
   PubMed Web of Science ®Google Scholar
• Steinbach W, Stevens D, Denning DW. Combination and sequential therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1996 to 2001. Clin Infect Dis 2003;37:S188-224
   PubMed Web of Science ®Google Scholar
• Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006;8:434-41
   PubMedGoogle Scholar
• Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005;131:201-7
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Eng J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter KR, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008;59:455-73
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Manavathu E. Voriconazole: a second generation triazole. Drugs Today 2001;37:135-48
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Final package insert for ERAXIS (anidulafungin) for injection. New York: 2006
   Google Scholar
• Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006;50:2058-63
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49:3264-73
   PubMed Web of Science ®Google Scholar
• Gardiner RE, Souteropoulos P, Park S, et al. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005;43(Suppl 1):S299-305
   PubMed Web of Science ®Google Scholar
• Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001;183:2273-7
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007;10:121-30
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano Chiu M, Paetznick V, et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327-30
   PubMed Web of Science ®Google Scholar
• Damle BD, Dowell JA, Walsky RL. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009;53:1149-56
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol 2007;45:2180-2
   PubMed Web of Science ®Google Scholar
• Estes KE, Penzak SR, Calis KA, et al. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacother 2009;1:17-30
   Google Scholar
• Gardiner RE, Souteropoulos P, Park S, et al. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005;43(Suppl 1):S299-305
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Abruzzo G, Flattery A, et al. Characterizsation of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996;64:3244-51
   PubMed Web of Science ®Google Scholar
• Messer SA, Moet GJ, Kirby JT, et al. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009;47:1942-6
   PubMed Web of Science ®Google Scholar
• Dowell J, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590-8
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Driscoll T, Seibel NL. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50:632-8
   PubMed Web of Science ®Google Scholar
• Damle B, Stogniew M, Dowell J. Pharmacokinetics and issue distribution of anidulafungin in rats. Antimicrob Agents Chemother 2008;52:2673-6
   PubMed Web of Science ®Google Scholar
• Damle BD, Dowell JA, Walsky RL. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009;53:1149-56
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007;47:461-70
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50:3695-700
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590-8
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1187-92
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of a concentration dependent activity. J Infect Dis 2004;190:1464-71
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45:2845-55
   PubMed Web of Science ®Google Scholar
• Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004a;48:2021-4
   PubMed Web of Science ®Google Scholar
• Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004b;39:770-5
   PubMed Web of Science ®Google Scholar
• Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:3-14
   Web of Science ®Google Scholar
• Reboli A, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for inavasive candidiasis. N Engl J Med 2007;356:2472-82
   PubMed Web of Science ®Google Scholar
• Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3:71-9
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Boyken L, et al. Effectiveness of anidulafungin in eradicating candida species in invasive candidiasis. Antimicrob Agents Chemother 2005;49:4795-7
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunpharmacology of modern antifungals. Clin Infect Dis 2008;47:226-35
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin mediated b-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008;198:186-92
   PubMed Web of Science ®Google Scholar
• Vfend. Available from: http://www.pfizer.com/files/products/uspi_vfend.pdf
   Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71
   PubMed Web of Science ®Google Scholar
• Leveque D, Nivoix Y, Jehl FM, et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84
   PubMed Web of Science ®Google Scholar
• Santani H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Eng J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21
   PubMed Web of Science ®Google Scholar
• Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, et al. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001;39:2431-8
   PubMed Web of Science ®Google Scholar
• van den Brink HJM, van Gorcom RFM, van den Hondel CA, et al. Cytochrome P450 enzyme systems in fungi. Fungal Genet Biol 1998;23:1-17
   PubMed Web of Science ®Google Scholar
• Fukuoka T, Johnston DA, Winslow CA, et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003;47:1213-9
   PubMed Web of Science ®Google Scholar
• Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int J Clin Pract 2004;58:74-80
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31
   PubMed Web of Science ®Google Scholar
• Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000;34:1032-43
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. 2008;61:616-20
   Google Scholar
• Leveque D, Nivoix Y, Jehl FM, et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, Guinea pig, dog and human. Drug Metab Dispos 2003;3:731-41
   Google Scholar
• Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29:198-210
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious disease society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31
   PubMed Web of Science ®Google Scholar
• Verweij PE, de Pauw BE, Meis JF. Voriconazole (Pfizer ltd). IDrugs 1999;2:925-37
   PubMedGoogle Scholar
• Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192-8
   PubMed Web of Science ®Google Scholar
• Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40:1141-7
   PubMed Web of Science ®Google Scholar
• Diaz-Pedroche C, Cisneros J, Lumbreras C. Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in spain. Rev Esp Quimioter 2003;18:3623-6
   Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-8
   PubMed Web of Science ®Google Scholar
• Cesaro S, Strugo L, Alaggio R, et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single center pdiatric experience. Support Care Cancer 2003;11:722-7
   PubMed Web of Science ®Google Scholar
• Eibl M, Auner HW, Zinke-Cerwenka W, et al. High risk AML complicated by pulmonary aspergillosis:successful treatment with nonmyeloblastive stem cell transplantation and long term administration of voriconazole. Ann Hematol 2004;83:133-6
   PubMed Web of Science ®Google Scholar
• Garbino J, Rohner P, Kolarova L, et al. Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy. Infection 2003;31:241-3
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ. Voriconazole treatment for less-common, emerging or refractory fungal infections. Clin Infect Dis 2003;36:1122-31
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54
   PubMed Web of Science ®Google Scholar
• Ha KC, White TC. Effects of azole antifungal drugs on the transition from yeast to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 1999;43:763-8
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004;126:165-75
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy of invasive aspergillosis. Clin Infect Dis 2004;39:797-802
   PubMed Web of Science ®Google Scholar
• Vazquez JA. Combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis 2008;46:1889-901
   PubMed Web of Science ®Google Scholar
• Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008;59:455-73
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45:1373-83
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-8
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Jost D, Dierich MP, et al. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother 2008;52:1873-5
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungn in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004;10:925-8
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004;48:970-8
   PubMed Web of Science ®Google Scholar
• Fianchi L, Montini L, Caira M, et al. Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. Infection 2008;36:65-7
   PubMed Web of Science ®Google Scholar
• Schilling A, Seibold M, Mansmann V, et al. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol 2008;46:79-83
   PubMed Web of Science ®Google Scholar
• López-Ciudad V, Castro-Orjales MJ, León C, et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006;11:73
   Google Scholar
• Gubler C, Wildi SM, Imhof A, et al. Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole. Infection 2007;35:364-6
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, et al. Safety and pharmaconkinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45:1373-82
   PubMed Web of Science ®Google Scholar
• van de Sande WW, Mathot RA, ten Kate MT, et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009;53:2005-13
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlation of the concentration and dose dependent interaction between anidulafungin and voriconazole by bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009;53:2382-91
   PubMed Web of Science ®Google Scholar